(A) BE2 orthotopic xenograft. Tumor radiance was measured after 32 days of growth using luciferase imaging (photons/s/cm²/steradian), and the measurement was used to calculate the fold change in tumor radiance after 10, 17, 24, and 32 days of treatment with PBS or 1 mg/mouse/day of ODSH. Mann-Whitney U test, *P < 0.05 versus control at all time points. Luminescence images on day 24 of treatment. Survival until humane endpoints as a percentage of each condition. Treatment was stopped after 35 days (red arrow). Ki67 staining of xenograft sections. Original magnification, ×20; scale bar: 50 μM. Quantification of stain intensity using ImmunoRatio software. Data are presented as the mean of 3 sections ± SEM. *P < 0.05 versus control by 2-tailed Student’s t test. (B) SK-N-AS orthotopic xenograft. Tumor radiance was measured after 28 days of growth using luciferase imaging (photons/s/cm²/steradian), and the measurement was used to calculate the fold change after 7 and 11 days of treatment with PBS or 1 mg/mouse/day of ODSH. Luminescence images on day 7 of treatment. Survival until humane endpoints as a percentage of each condition. (C) H&E-stained organs from xenografted mice treated with PBS control or ODSH. Parentheses indicate the number of mice with AS or BE2 cell metastasis to the indicated organ. Arrows point to metastases. Original magnification, ×10; scale bar: 200 μM. (D) Western blots for differentiation and signaling markers in lysates from SK-N-AS and BE2 xenografts. Densitometry normalized to β-actin is shown as the percentage of control. (E) Images of tumor radiance in a pair of mice with a similar original tumor size in the SK-N-AS experiment. Injections were stopped after 32 days of treatment (day 60).